John joined Bicycle Therapeutics as CEO on formation of the company, prior to this he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD in which capacity he established the current GSK monoclonal antibody programme and was responsible for all biology support for biopharm discovery and development programmes from target to proof of concept
